By looking at the McNemar test table (Table 2), it shows that out of the 47 patients who were having normal Hb levels before the initiation of their treatment, 39 patients (83.0%) developed anemia during the course of therapy, and the remaining eight patients (17.0%) continued to be normal. Here, GSTM1 is linked to anemia.